VRDN•benzinga•
RBC Capital Maintains Outperform on Viridian Therapeutics, Lowers Price Target to $45
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 7, 2025 by benzinga